Advertisement


Michael R. Bishop, MD, on Aggressive B-Cell NHL: Tisagenlecleucel vs Standard of Care as Second-Line Therapy

2021 ASH Annual Meeting & Exposition

Advertisement

Michael R. Bishop, MD, of the University of Chicago, discusses insights from findings of the phase III BELINDA study, which may inform the design of future CAR T-cell trials, as well as the use of second-line tisagenlecleucel therapy in patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (Abstract LBA-6).



Related Videos

Leukemia
Genomics/Genetics

Eunice S. Wang, MD, on FLT3-Mutated AML: Gilteritinib and Azacitidine for Intensive Induction Chemotherapy–Ineligible Patients

Eunice S. Wang, MD, of Roswell Park Comprehensive Cancer Center, discusses phase III results showing that gilteritinib and azacitidine led to significantly higher composite complete response rates in patients with newly diagnosed FLT3-mutant acute myeloid leukemia who are ineligible for intensive induction chemotherapy. Overall survival was similar to that of azacitidine alone (Abstract 700).

 

Lymphoma
Immunotherapy

Roni Shouval, MD, PhD, on TP53-Mutant Large B-Cell Lymphoma and CAR T-Cell Therapy

Roni Shouval, MD, PhD, of Memorial Sloan Kettering Cancer Center, discusses his findings, which show, for the first time, that TP53 alterations are a valuable prognostic and potentially predictive marker in patients with large B-cell lymphoma who receive CD19–CAR T-cell therapy. Gene-expression profiling suggests that TP53 alterations result in an immunosuppressive tumor microenvironment and impaired apoptosis signaling, which could lead to decreased CAR T-cell therapy efficacy (Abstract 710).

Leukemia
Genomics/Genetics

Talha Badar, MD, on TP53-Mutated AML and the Impact of Allogeneic Stem Cell Transplantation on Survival

Talha Badar, MD, of the Mayo Clinic, discusses the near-universal poor outcomes for patients with TP53-mutated acute myeloid leukemia and the findings that show allogeneic stem cell transplantation appears to improve the long-term survival in a subset of these patients. Effective therapies may successfully bridge patients to transplant and prolong survival for those who are transplant-ineligible (Abstract 797).

Lymphoma

Tycel Phillips, MD, on Marginal Zone Lymphoma: Efficacy and Safety of Parsaclisib

Tycel Phillips, MD, of the Rogel Cancer Center, University of Michigan, discusses phase II findings from the CITADEL-204 study of parsaclisib, a next-generation inhibitor of phosphatidylinositol 3-kinase. The agent, used as a monotherapy, appeared to benefit patients with relapsed or refractory marginal zone lymphoma who had a rapid and durable clinical response (Abstract 44).

Lymphoma
Immunotherapy

L. Elizabeth Budde, MD, PhD, on Relapsed/Refractory Follicular Lymphoma: Early Results on Mosunetuzumab Monotherapy

L. Elizabeth Budde, MD, PhD, of City of Hope, discusses phase I/II findings that showed mosunetuzumab monotherapy induces deep and durable remissions in patients with relapsed or refractory follicular lymphoma who have received two or more prior lines of treatment, including those with double-refractory disease. Because follicular lymphoma is associated with frequent relapses and decreasing progression-free intervals with successive lines of conventional therapy, these data are encouraging (Abstract 127).

Advertisement

Advertisement




Advertisement